Litigation

Celgene Corp. v. Aurobindo Pharma Ltd. et al.

settled

2:20-cv-00315

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Filed
2020-01-08
Terminated
2021-07-19

Patents at issue (1)

7855217

Plaintiffs (1)

Summary

Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).